The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Share
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
Keeping Aging Federal Systems Running Amid OT Vulnerabilities
A techno-thriller novel highlights how organizational silos can become critical infrastructure vulnerabilities in the AI era.
19m watch -
HHS Looks to Centralize IT Buying, Speed Access to Emerging Tech
HHS is centralizing IT procurement while pursuing faster acquisition tools for AI and other emerging technologies.
9m watch -
VA Employees Save 6 Hours a Week With AI Tools
VA AI chief Kimberly McManus said AI tools are helping improve veteran care, reduce opioid overdose mortality and save time for employees.
4m watch -
FEHRM CTO: TEFCA Could Take Federal Health Data Exchange to ‘Next Evolution’
FEHRM CTO Lance Scott discusses efforts to modernize and improve interoperability of electronic health records across the federal government.
7m watch